Skip to main content
Submitted by PatientsEngage on 1 November 2017

Dr. V. L. Ramprasad, COO of MedGenome, a genomics-based diagnostics and research company, highlights the importance of genetic testing. Genetic testing can be useful in identifying genetic disorders, inherited diseases and abnormalities and helpful in management, treatment or prevention of diseases, especially cancers.

What is the difference between genetic testing and genome sequencing?

Genetic testing is an investigation that looks at specific set of gene variations or set of genes or the complete genome of an individual and correlate it with the disease/trait the individual has and generate an actionable report that helps in management, treatment or prevention of the disease. Genome sequencing (Read - Whole genome sequencing) is a general term used for sequencing a whole genome of an individual for various applications.

Why and when is genome sequencing recommended?

There are different flavours of dissecting a genome. Human Genome has 3X109 DNA elements (also called as 3Giga bases). These comprise of those regions in the genome which code for a protein and which don’t. For several genetic diseases we know the exact genetic defects, so one can look at only those genes to identify for the defects by doing targeted sequencing that investigates on selective regions of the complete genome.

In several situations we cannot pin point the exact diagnosis of the genetic disease (Undiagnosed diseases) and hence do not know which specific regions to look at in the whole genome, in those situations we do complete genome sequencing.

What are the benefits of genetic testing?

  • Genetic testing can help in predicting the disease (especially in the unborn, foetal testing or other first degree relatives)
  • Helps in better treatment of the disease especially in cancers. Based on the genetic mutation targeted therapies in cancer are effective compared to regular chemotherapy.
  • Genetic testing refines the diagnosis and pin points the exact diagnosis thereby arriving at the appropriate treatment and management decisions.

Rare diseases in India are not so rare. Why?

A rare disease occurs infrequently in a population, but there is no universal definition. It depends on the total number of people having the disease and its prevalence.

The World Health Organization (WHO) has suggested that a rare disease should be defined as one with frequency less than 6.5 – 10 per 10,000 people. In USA, it is defined as any disease or condition that affects less than 200,000 persons. The affected numbers in Japan are 50,000 people, 20,000 in Korea ,10,000 in Taiwan and 2000 in Australia.

Thus, a country defines a rare disease most appropriate in the context of its own population, health care system and resources. Unfortunately India doesn’t have a definition of rare disease, if we consider the above definitions, several diseases that are considered rare in US are not rare because of sheer size of the population and high prevalence rates.

Can you list some of the rare disease that you have come across?

Canavan disease
Lysosomal storage diseases
Haemophilia
Tay sachs disease
Diamon Blackfann anaemia
Muscular Dystrophies

What is the cost of genome sequencing?

Whole genome sequencing costs 1000-1300 USD
Sequencing on the protein coding regions (called as Exome sequencing) costs 500-600 USD

What are the common misconceptions on genetic testing?

Once we know the mutation it can be fixed and treatment is available: Currently you cannot fix a mutation that is seen in the germ cells of the individual, even though there are new technologies that have shown the promise to repair, they are yet to arrive in clinic.

The test always gives a conclusive result: currently the diagnostic yield of the tests vary depending on the test and the disease, so one may not get conclusive result all the time.

Condition

Stories

  • Esophageal Cancer Made Swallowing Of Even Ice Cream Hard
    When Mr. Sudhir Waghmare, 58, PhD, entrepreneur and innovator, was diagnosed with esophageal cancer he took it in his stride quite stolidly. What broke him down was the loss during chemotherapy of his luscious hair which he dearly cherished. He shares his personal narrative. My background I am an entrepreneur and innovator of a company engaged in manufacturing new born life saving devices since the last 31 years. I have a PhD degree in Neonatal Intensive care equipment. I am married to…
  • मैं कैंसर से नहीं मरूंगी
    मुंबई की 56 वर्षीय रश्मि सचदे को 15 साल पहले गैस्ट्रोइंटेस्टाइनल स्ट्रोमल ट्यूमर (जीआईएसटी) का निदान मिला था। वे कैंसर को एक पेइंग गेस्ट की तरह मानती हैं और अपनी कैंसर यात्रा को अपनी आस्था और हँसते रहने की प्रवृत्ति के सहारे संभालती हैं। 2004 की बात है।, मैंने देखा कि मेरा पेट फूलने लगा था और जब मैं सोने के लिए लेटती तो विशेष रूप से एक तरफ बहुत सख्त लगता। मुझे उस समय फूले हुए पेट के अलावा कोई अन्य स्वास्थ्य संबंधी शिकायत नहीं थी – पर पेट इतना फूला रहता कि लोग पूछने लगे कि क्या मैं गर्भवती हूं।…
  • Profile picture of Uday Kerwar Bladder cancer survivor and Ostomy India Chairperson framed in a blue background with the bladder cancer tricolour ribbon
    You Adapt To The Bladder Bag Like You Do To Eye-Glasses
    Uday Kerwar, survivor of stage 4 bladder cancer and currently Chairman of Ostomy Association of India (OAI) talks about his journey with bladder cancer, urostomy bags, its many challenges and plenty of adjustments before it becomes a part of you. Please tell us a little about yourself.  I am 62 and retired. Since 2016 I am continuously associated with Ostomy Association of India (OAI), a Charitable Trust providing rehabilitative support to people who have undergone Ostomy (life-saving…
  • Head shot of a bespectacled woman wearing a black and red dress and red necklace
    मेरे ब्रेन ट्यूमर के निदान ने मुझे बोल्ड बना दिया
    जब बेंगलुरु की 38 वर्षीया ए चित्रा को सीज़र होने लगे, तो शुरू में उनका एपिलेप्सी (मिर्गी) के लिए इलाज किया गया, लेकिन अंततः उन्हें मैलिग्नेंट ग्लियोमा (एक प्रकार का ब्रेन ट्यूमर) का निदान मिला। वे बताती हैं कि कैसे उन्होंने डॉक्टरों, परिवार, दोस्तों और अपनी कंपनी की टीम के समर्थन से अपनी बीमारी के उपचार और भावनात्मक पीड़ा को संभाला। कृपया हमें अपनी स्थिति के बारे में कुछ बताएं मुझे एनाप्लास्टिक एस्ट्रोसाइटोमा ग्रेड 3 नामक ब्रेन ट्यूमर का निदान मिला था। यह एक दुर्लभ, मैलिग्नेंट ट्यूमर है जिसे…
  • ब्रेन ट्यूमर होने के बाद मेरी पहली प्राथमिकता मेरा स्वास्थ्य है
    30 वर्षीय मेल्विन जॉर्ज इस लेख में एस्ट्रोसाइटोमा (एक प्रकार का ब्रेन ट्यूमर) का निदान प्राप्त करने, देखभाल के विकल्पों का आकलन करने और निर्णय लेने, और कैंसर के उपचार और सम्बंधित दुष्प्रभाव पर चर्चा करते हैं और साझा करते हैं  कि इन सब अनुभव और चुनौतियों ने उन्हें व्यक्तिगत रूप से कैसे प्रभावित किया और रिकवरी में उनकी आस्था उनका मुख्य सहारा कैसे बनी रही।  चौंकाने वाला निदान 11 जुलाई 2017 का दिन। मैं अपने छात्रावास के कमरे में अपने बिस्तर पर लेटा हुआ था और जैसे ही मैं जाका, मैंने देखा…
  • The author, a woman in a red and yellow sari and a yellow blouse, holding birds
    मैंने अपनी आवाज पैसिव स्मोकिंग (निष्क्रिय धूम्रपान) के कारण खो दी
    धूम्रपान न करने वाली 72 वर्षीया नलिनी सत्यनारायण को 10 साल पहले उनके घर में सेकेंड हैंड धुएं के संपर्क में आने के कारण गले (वॉयस बॉक्स) के कैंसर का निदान मिला। आज, उत्तरजीवी के रूप में, वे एक ऊर्जावान तंबाकू नियंत्रण योद्धा बन गई हैं और ऐसे लोगों को परामर्श देती हैं जिन्होंने स्वरयंत्र (लैरिन्क्स) की सर्जरी करवाई है जिसमें उनका वॉयस बॉक्स हटाया गया है - वे उन्हें कृत्रिम वॉयस बॉक्स से बात करना सिखाती हैं। आपने कब और कैसे अपने गले की समस्या को पहचाना? जनवरी 2010 की बात है। मुझे लगा कि मेरा गला…
  • Should Time Toxicity Be A Factor In Informed Decision Making?
    Patients with advanced cancers often contemplate the time burden of their cancer care. What does this exactly entail? Dr Arjun Gupta, an Oncologist and Researcher, recently wrote a paper about Time Toxicity for Cancer patients. He helps us understand this new concept and how it can affect quality of life for patients. What is ‘’time toxicity’’? We have seen tremendous progress in oncology in the past few decades. Yet, for advanced solid cancers, average survival benefits offered by new…
  • Webinar: Ovarian Cancer Awareness and Management
    This webinar is not just for Ovarian Cancer survivors but also for survivors of breast cancer, uterine cancer, colorectal cancer and all women at risk of Ovarian Cancer. Ovarian Cancer is a difficult to diagnose cancer. So it is very important for us to be aware of the surprising symptoms of Ovarian cancer. We must also know the factors that increase risk. Additionally, in COVID times, it is important to understand how to continue treatment and when you should vaccinate. We bring together a…
  • A panel discussion on Kidney Cancer with the profile pictures of the panelists
    Demystifying Kidney Cancer : Key Webinar takeaways
    Renal cell carcinoma is the most common type of adult kidney cancer, making up about 85% of diagnoses. And yet it is rarely talked about.  Kidney Cancer is also an area which has seen significant progress in treatment options. Key takeaways from the webinar are given below.  An expert panel talked about kidney cancer and answered questions and concerns that patients have. The panelists are Dr. KL Jayakumar, MD Radiation Oncology. Professor and HOD, Sreemookambika Cancer center,…
  • Webinar: Towards Patient Centred Access To Quality Cancer Care - Challenges
    PatientsEngage and EHA Consortium invite you to an interactive webinar series on Patient Centred Access to Quality Cancer Care. In the first of the series aligned to the UICC theme of "Close the Care Gap", we are very privileged to have an esteemed and diverse panel who will highlight the challenges faced in equitable access to quality cancer care and identify the areas where we still need to make progress. The panelists are Dr. CS Pramesh, Director Tata Memorial Hospital; Convener National…